KEYNOTE-199 phase II study studied the effect of pembrolizumab in 258 men with docetaxel-refractory metastatic prostate cancer suggesting higher efficacy of pembrolizumab in patients with PD-L-1 overexpression or disease spread to the bones [78]. The gene discussed is CD274; the disease is metastatic prostate carcinoma.